These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 32220831)

  • 1. Pancreatic Adenocarcinoma: Unconventional Approaches for an Unconventional Disease.
    Gromisch C; Qadan M; Machado MA; Liu K; Colson Y; Grinstaff MW
    Cancer Res; 2020 Aug; 80(16):3179-3192. PubMed ID: 32220831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future.
    Christenson ES; Jaffee E; Azad NS
    Lancet Oncol; 2020 Mar; 21(3):e135-e145. PubMed ID: 32135117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
    Chandana S; Babiker HM; Mahadevan D
    Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.
    Ruess DA; Görgülü K; Wörmann SM; Algül H
    Drugs Aging; 2017 May; 34(5):331-357. PubMed ID: 28349415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
    Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
    J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer.
    Adiseshaiah PP; Crist RM; Hook SS; McNeil SE
    Nat Rev Clin Oncol; 2016 Dec; 13(12):750-765. PubMed ID: 27531700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions.
    Zhang Y; Yang C; Cheng H; Fan Z; Huang Q; Lu Y; Fan K; Luo G; Jin K; Wang Z; Liu C; Yu X
    J Hematol Oncol; 2018 Jan; 11(1):14. PubMed ID: 29386069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impacting Pancreatic Cancer Therapy in Heterotypic
    Obaid G; Bano S; Mallidi S; Broekgaarden M; Kuriakose J; Silber Z; Bulin AL; Wang Y; Mai Z; Jin W; Simeone D; Hasan T
    Nano Lett; 2019 Nov; 19(11):7573-7587. PubMed ID: 31518145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KRAS-related proteins in pancreatic cancer.
    Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
    Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
    Indolfi L; Ligorio M; Ting DT; Xega K; Tzafriri AR; Bersani F; Aceto N; Thapar V; Fuchs BC; Deshpande V; Baker AB; Ferrone CR; Haber DA; Langer R; Clark JW; Edelman ER
    Biomaterials; 2016 Jul; 93():71-82. PubMed ID: 27082874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma.
    Zhen DB; Coveler A; Zanon S; Reni M; Chiorean EG
    Semin Oncol; 2018 Jun; 45(3):107-115. PubMed ID: 30391013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging antibodies for the treatment of pancreatic cancer.
    Andrikou K; Peterle C; Pipitone S; Salati M; Cascinu S
    Expert Opin Emerg Drugs; 2017 Mar; 22(1):39-51. PubMed ID: 28253833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic targeting of STAT3 pathways in pancreatic adenocarcinoma: A systematic review of clinical and preclinical literature.
    Peisl S; Mellenthin C; Vignot L; Gonelle-Gispert C; Bühler L; Egger B
    PLoS One; 2021; 16(6):e0252397. PubMed ID: 34138876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stem cell-directed therapies in pancreatic cancer.
    Kumar R; Dholakia A; Rasheed Z
    Curr Probl Cancer; 2013; 37(5):280-6. PubMed ID: 24331183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of nano engineered approaches to overcome the stromal barrier in pancreatic cancer.
    Meng H; Nel AE
    Adv Drug Deliv Rev; 2018 May; 130():50-57. PubMed ID: 29958925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics.
    Ocal O; Pashkov V; Kollipara RK; Zolghadri Y; Cruz VH; Hale MA; Heath BR; Artyukhin AB; Christie AL; Tsoulfas P; Lorens JB; Swift GH; Brekken RA; Wilkie TM
    Dis Model Mech; 2015 Oct; 8(10):1201-11. PubMed ID: 26438693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanomedicine and epigenetics: New alliances to increase the odds in pancreatic cancer survival.
    Urbanova M; Cihova M; Buocikova V; Slopovsky J; Dubovan P; Pindak D; Tomas M; García-Bermejo L; Rodríguez-Garrote M; Earl J; Kohl Y; Kataki A; Dusinska M; Sainz B; Smolkova B; Gabelova A
    Biomed Pharmacother; 2023 Sep; 165():115179. PubMed ID: 37481927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The trend toward more target therapy in pancreatic ductal adenocarcinoma.
    Deiana C; Agostini M; Brandi G; Giovannetti E
    Expert Rev Anticancer Ther; 2024 Jul; 24(7):525-565. PubMed ID: 38768098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Therapies for Pancreatic Cancer and Hurdles Ahead.
    Aslan M; Shahbazi R; Ulubayram K; Ozpolat B
    Anticancer Res; 2018 Dec; 38(12):6591-6606. PubMed ID: 30504367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma.
    Gautam SK; Kumar S; Cannon A; Hall B; Bhatia R; Nasser MW; Mahapatra S; Batra SK; Jain M
    Expert Opin Ther Targets; 2017 Jul; 21(7):657-669. PubMed ID: 28460571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.